The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL

Brickner, Anthony G.

doi:10.1182/blood-2005-08-3501

Cited by 98 publications

(81 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This approach has been used to identify a large number of individual peptide antigens that are presented by class I MHC molecules and recognized by CD8 T cells. These include: transplantation antigens recognized by T cells during the course of tissue graft rejection and graft versus host disease [26,[49][50][51][52][53][54][55][56][57]; antigens expressed on melanoma [43,[58][59][60], lung carcinoma [61], colon carcinoma [62], breast and other epithelial carcinomas [63], and UV-induced sarcoma [64]; antigens derived from intracellular bacteria [65,66]; and antigens recognized during the development of autoimmune diabetes [67]. A similar approach has enabled the identification of peptide antigens presented by class II MHC molecules and recognized by CD4 T cells [68].…”

Section: Identification Of Peptides Recognized By Specific T Lymphocytesmentioning

confidence: 99%

The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes

Engelhard

2007

International Journal of Mass Spectrometry

View full text Add to dashboard Cite

Over the last 15 years, the ability of mass spectrometry to analyze complex peptide mixtures and identify individual species has provided unprecedented insights into the repertoire of peptide antigens displayed by MHC molecules and recognized by T lymphocytes. These include: understanding the peptide binding specificity of MHC molecules; understanding of roles of different intracellular components of the antigen processing pathways in determining the peptide display; and identification of a large number of individual peptide antigens associated with infectious diseases, cancer, and transplant rejection that have provided the basis for new immunologically based therapies. This review will summarize the impact that the application of mass spectrometry has had on these advances, with particular attention to the contributions of Professor Donald Hunt and members of his laboratory, and point out the opportunities for future work. Keywordsantigen processing; post-translational modification; peptides; MHC molecules THE NATURE OF ANTIGEN RECOGNITION BY T LYMPHOCYTEST lymphocytes are a branch of the immune system concerned with recognition of antigens that are displayed on the surface of host cells. These antigens are produced through intracellular proteolytic mechanisms that create small peptides, which are then rescued and presented at the cell surface by adaptor proteins called MHC molecules [reviewed in [1-6]. The binding site of each MHC molecule enables it to bind to a wide range of different peptides, and results in the display of a repertoire of such antigens, each recognized by a distinct T lymphocyte. This "antigen processing and presentation" mechanism results in the display of peptides derived from the proteins of pathogens that have infected the cell or been taken up by endocytosis. Their recognition by T lymphocytes results in the development of an immune response, and results in clearance of the pathogen and infected cells from the body. However, antigen processing and presentation pathways operate constitutively on normal cellular proteins as well, resulting in the display of peptide antigens that can be distinguished on tumors and transplanted tissues. Some of these "self-peptides" are also involved in the development of T lymphocytes in the thymus, and their recognition also controls the balance between selftolerance and autoimmune disease. Correspondence: phone: 434-924-2423; fax: 434-924-1221; email: vhe@virginia.edu Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. In most individuals, molecules of each MHC class are expressed from 3 genetic loci that ...

show abstract

Section: Identification Of Peptides Recognized By Specific T Lymphocytesmentioning

confidence: 99%

The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes

Engelhard

2007

International Journal of Mass Spectrometry

View full text Add to dashboard Cite

show abstract

“…These mHags are polymorphic peptides that differ between patient and donor, and are able to elicit CD8 ϩ or CD4 ϩ donor T-cell responses in the context of self-HLA. 4 A variety of HLA-class I-restricted mHags have been identified, [5][6][7][8][9][10][11][12][13][14][15][16][17] and the appearance of CD8 ϩ T cells specific for several of these mHags was closely followed by complete remissions of the malignancies, 12,14,16,18 indicating the clinical relevance of these T cells.…”

Section: Introductionmentioning

confidence: 99%

Identification of 4 new HLA-DR–restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity

Stumpf

Meijden

Bergen

et al. 2009

Blood

View full text Add to dashboard Cite

“…3 In an effort to expand the patient population for HA-1-based immunotherapy, a decameric peptide containing His at position 6 from the same polymorphic region has been identified as an mHA presentable by the HLA-B60 molecule. 5 The only other mHAs with selective expression in hematopoietic cells described to date are HA-2, 6,7 BCL2A1 (ACC-1 and ACC-2), 8,9 HB-1 10,11 and PANE1, 12 the latter two of which are B cell lineage-specific. Thus, identification of novel hematopoietic system-specific mHAs is warranted to facilitate the development of effective immunotherapy to induce GVL reactions.…”

Section: Introductionmentioning

confidence: 99%

The HLA-A0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A0206

Torikai

Akatsuka

Miyauchi

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL

Cited by 98 publications

References 41 publications

The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes

The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes

Identification of 4 new HLA-DR–restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity

The HLA-A0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A0206

Contact Info

Product

Resources

About

The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL

Cited by 98 publications

References 41 publications

The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes

The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes

Identification of 4 new HLA-DR–restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity

The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206

Contact Info

Product

Resources

About

The HLA-A0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A0206